H
Hideki Enokida
Researcher at Kagoshima University
Publications - 224
Citations - 12728
Hideki Enokida is an academic researcher from Kagoshima University. The author has contributed to research in topics: microRNA & Cancer. The author has an hindex of 65, co-authored 196 publications receiving 11432 citations. Previous affiliations of Hideki Enokida include San Francisco VA Medical Center & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Small dsRNAs induce transcriptional activation in human cells
Long-Cheng Li,Steven T. Okino,Hong Zhao,Deepa Pookot,Robert F. Place,Shinji Urakami,Hideki Enokida,Rajvir Dahiya +7 more
TL;DR: A more diverse role for small RNA molecules in the regulation of gene expression than previously recognized is revealed and a potential therapeutic use for dsRNA in targeted gene activation is identified.
Journal ArticleDOI
miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma
Masayuki Kano,Naohiko Seki,Naoko Kikkawa,Lisa Fujimura,Isamu Hoshino,Yasunori Akutsu,Takeshi Chiyomaru,Hideki Enokida,Masayuki Nakagawa,Hisahiro Matsubara +9 more
TL;DR: The identification of tumor‐suppressive miRNAs,miR‐145, miR‐133a and miR-133b, directly control oncogenic FSCN1 gene, and could provide new insights into potential mechanisms of ESCC carcinogenesis.
Journal ArticleDOI
Identification of novel microRNA targets based on microRNA signatures in bladder cancer.
Takahiro Ichimi,Hideki Enokida,Yasushi Okuno,Ryo Kunimoto,Takeshi Chiyomaru,Ken Kawamoto,Kazuya Kawahara,Kazuki Toki,Kazumori Kawakami,Kenryu Nishiyama,Gozoh Tsujimoto,Masayuki Nakagawa,Naohiko Seki +12 more
TL;DR: The target search algorithm and gene‐expression profiling in BCs revealed that Keratin7 (KRT7) mRNA was a common target of the downregulated miRNAs, and the mRNA expression levels of KRT7 were significantly higher inBCs than in NBEs.
Journal ArticleDOI
miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer
Takeshi Chiyomaru,Hideki Enokida,S. Tatarano,Kazuya Kawahara,Yousuke Uchida,Kenryu Nishiyama,Lisa Fujimura,Naoko Kikkawa,Naohiko Seki,Masayuki Nakagawa +9 more
TL;DR: Tumour suppressivemiR-145 and miR-133a directly control oncogenic FSCN1 in BC, and both microRNAs repressed the mRNA and protein expression of F SCN1.
Journal ArticleDOI
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
Thomas Powles,Michiel S. van der Heijden,Daniel Castellano,Matthew D. Galsky,Yohann Loriot,Daniel P. Petrylak,Osamu Ogawa,Se Hoon Park,Jae-Lyun Lee,Ugo De Giorgi,Martin Bögemann,Aristotelis Bamias,Bernhard J. Eigl,Howard Gurney,Som D. Mukherjee,Yves Fradet,Iwona Skoneczna,Marinos Tsiatas,Andrey Novikov,Cristina Suarez,Andre P. Fay,Ignacio Duran,Andrea Necchi,Sophie Wildsmith,Philip He,Natasha Angra,Ashok K. Gupta,Wendy Levin,Joaquim Bellmunt,Jae-Lyun Lee,Hans Westgeest,Aude Flechon,Yen-Chuan Ou,Inkeun Park,Vsevolod Matveev,Begoña Perez-Valderrama,Susanna Cheng,Stephen Jay Frank,Urbano Anido,Alketa Hamzaj,Margitta Retz,Srikala S. Sridhar,Giorgio V. Scagliotti,Jens Voortman,Boris Alekseev,Anna Alyasova,Boris Komyakov,Herlinde Dumez,Michel Pavic,Go Kimura,Atsushi Mizokami,Susanne Osanto,Jose Angel Arranz,Djura Piersma,Sang Joon Shin,Oleg Karyakin,Ignacio Delgado,Jose Luis Gonzalez,See-Tong Pang,Anna Tran,Oleg Lipatov,Wen Pin Su,Thomas W. Flaig,Ajjai Alva,Hwa Park Kyong,Evgeny Kopyltsov,Elena Almagro,Monserrat Domenech,Yen-Hwa Chang,Brieuc Sautois,Andre Ravaux,Gerasimos Aravantinos,Vasileios Georgoulias,Sasja Mulder,Yu Jung Kim,Fabio Kater,Christine Chevreau,Scott T. Tagawa,Pawel Zalewski,Florence Joly,Gencay Hatiboglu,Luca Gianni,Franco Morelli,Rosa Tambaro,Yasuhiro Hashimoto,Alexander Nosov,Albert Font,Alejo Rodriguez-Vida,Robert Jones,Naveen S. Vasudev,Sandhya Srinivas,Jingsong Zhang,Thierry Gil,Daygen Finch,Marc-Oliver Grimm,Yu-Li Su,Simon Chowdhury,Christopher Hocking,Eugen Plas,Scott North,Niels Viggo Jensen,Christine Theodore,Florian Imkamp,Avivit Peer,Takashi Kobayashi,Hideki Sakai,Naoto Sassa,Kazuhiro Yoshimura,Maureen J.B. Aarts,Ana Ferreira Castro,Marlen Topuzov,Juan Francisco Rodriguez,Federico Vazquez,Yu-Chieh Tsai,Simon J. Crabb,Syed A. Hussain,Johanna C. Bendell,Marine Gross-Goupil,Gravis Gwenaelle,Raanan Berger,Galina Statsenko,Linda Evans,Alexandra Drakaki,Bradley Somer,Ian D. Davis,James Lynam,Giuliano Santos Borges,Aldo Dettino,Graziella Martins,Luis Eduardo Zucca,Mads Agerbæk,Haralambos Kalofonos,Eli Rosenbaum,Hideki Enokida,Hiroaki Kikukawa,Kazuo Nishimura,Satoshi Tamada,Motohide Uemura,Yamil Lopez,Jourik A. Gietema,Marcin Slojewski,Isabel Fernandes,Alexey Smolin,Danish Mazhar,Arash Rezazadeh Kalebasty,Bradley Carthon,Wolfgang Loidl,Fabio Franke,Gustavo Girotto,Nimira S. Alimohamed,Robyn Macfarlane,Helle Pappot,Guenter Niegisch,Dimitrios Mavroudis,Avishay Sella,Camillo Porta,Shin Ebara,Motonobu Nakamura,Wataru Obara,Norihiko Okuno,Nobuo Shinohara,Mikio Sugimoto,Akitaka Suzuki,Noriaki Tokuda,Hiroji Uemura,Akito Yamaguchi,Francisco Ramirez,Pawel Rozanowski,Paweł Wiechno,Bhumsuk Keam,Nikolay Kislov,Denis Plaksin,Irfan Cicin,Satish Kumar,Joseph Rosales,Ulka N. Vaishampayan,Stéphane Culine,Christos Papandreou,Taketoshi Nara,Mustafa Erman,Laurence Kreiger,Juliana Janoski,Diogo Rosa,Mariana Siqueira,Christina Canil,Lisa Sengeløv,Jean-Marc Tourani,Gaku Arai,Katsuyoshi Hashine,Mutsushi Kawakita,Noboru Nakaigawa,Hayahito Nomi,Hiroaki Shiina,Hiroyoshi Suzuki,Junji Yonese,Roberto Kuri,Eleazar Macedo,Samuel Rivera,Alberto Villalobos Prieto,Anna Polakiewicz-Gilowska,Renata Zaucha,Fabio Lopes,Roman Ponomarev,Mark Pomerantz,Shahrokh F. Shariat,Cynthia Luk,Krzysztof Lesniewski-Kmak +206 more
TL;DR: The overall survival of patients who received durvalumab (a PD-L1 inhibitor), with or without tremelimumab ( a CTLA-4 inhibitor), as a first-line treatment for metastatic urothelial carcinoma was assessed.